BioPharm Reports (VennBio Ltd.), Feb 2010, Pages: 114
understand how current drugs and combinations can best be used to target mild, moderate and severe stages. Knowledge in these areas is also important to drug developers, who seek a better understanding
BioPharm Reports (VennBio Ltd.), June 2010, Pages: 114
developers, who seek a better understanding of patient needs and outcomes as part of their own efforts to develop more effective therapies. The present survey was carried out to meet interest in these areas
Jain PharmaBiotech, Feb 2012, Pages: 534
centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.
Over 300 different compounds are at various stages of development for the treatment of Alzheimer
Jain PharmaBiotech, Feb 2012, Pages: 628
product or products along with 110 collaborations. Some of the products in development at academic institutions that do not have a commercial sponsor are also included. Although an up-to-date search
John Wiley and Sons Ltd, Aug 2010, Pages: 355
Metabolism.
6.5 Efficacy and Safety.
6.6 Syntheses.
6.7 References.
Chapter 7. Sunitinib (Sutent), An Angiogenesis Inhibitor (Martin Pettersson).
7.1 Background.
7.2 Discovery and Development.
7
Draco Healthcare Consulting LLC, April 2009, Pages: 140
Information has developed and maintained (China Nan Fang Institute is a direct subsidiary of the Chinese State Food and Drug Administration, the SFDA). Sampled hospitals are from major Chinese cities across
Business Monitor International, April 2010, Pages: 86
, galantamine, pramipexole, prednisone and tizanidine in over 200 presentations. Risks to the forecasts are mostly on the downside, due to the challenging pricing and reimbursement environment, although generics
Renub Research, June 2011, Pages: 95
approved for Alzheimer’s disease, but it still remains a significant area of unmet medical need. Clinical success has proven elusive; however, numerous companies are developing novel treatments. Currently
Informa Healthcare, Sep 2004, Pages: 774
, K.K.Y. Ling, E.K.K. Tung, L.W. Kong, and E.A. Barnard
Control of Expression of Nicotinic Receptor and Acetylcholinesterase in the Developing Neuromuscular Junction in the Human Muscle, Z. Grubic, K
